ClinicalTrials.gg

Program

remigromig

Its studies are mostly in Macular Edema · Macular Degeneration · Retinal Vein Occlusion, led by Merck.

Furthest: phase 3, since Aug 20, 20244 company-led studies, 3 open or runningNext primary completion: Jan 11, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck43 open or runningphase 3since Aug 20, 2024Jun 14, 2023Jan 11, 2027phase 3 · NCT06957080
  • Named in Merck’s own pipeline as remigromig (MK-3000), phase 3, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 14, 2023First study: phase 2 study in Macular DegenerationFirst studyNCT05919693 · 33 enrolled · United States, Argentina, Puerto Rico and more
  2. Aug 20, 2024Phase 3 study in Diabetic Macular Edema (DME)NCT06571045 · 984 enrolled · United States, Argentina, Australia and more
  3. Apr 16, 2025Phase 3 study in Diabetic Macular Edema (DME)NCT06957080 · 1,054 enrolled · United States, Argentina, Brazil and more
  4. Sep 24, 2025Phase 2 study in Retinal Vein OcclusionNCT07205887 · 160 planned · United States

Ahead

  1. Jan 11, 2027Primary completion: phase 3 study in Diabetic Macular Edema (DME)NCT06957080
  2. Jun 30, 2028Primary completion: phase 2 study in Retinal Vein OcclusionNCT07205887

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07205887Retinal Vein Occlusion · United States2RecruitingJun 30, 2028160
NCT06957080Diabetic Macular Edema (DME) · United States, Argentina, Brazil and more3Active, not recruitingJan 11, 20271,054
NCT06571045Diabetic Macular Edema (DME) · United States, Argentina, Australia and more3Active, not recruitingJul 14, 2026984
NCT05919693Macular Degeneration · United States, Argentina, Puerto Rico and more2CompletedAug 26, 202433

How it is read

Names in the registry

  • “Remigromig”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.